ROZLYTREK
PeakNDAORALCAPSULEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ROZLYTREK (entrectinib) is an oral small-molecule tyrosine kinase inhibitor approved in August 2019 for patients with NTRK fusion-positive solid tumors and ROS1-positive non-small cell lung cancer. The drug works by inhibiting tropomyosin receptor kinase (TRK) and ROS1 signaling pathways, blocking tumor cell proliferation in patients with these rare genomic alterations.
Peak11.7 years to LOE
Product is in peak commercial phase with established market presence, likely supporting mid-to-large brand team and indication expansion efforts.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ROZLYTREK offers exposure to specialized oncology commercialization in a rare-disease genomics space with a high-touch, physician-education model. Career development benefits from a stable, peak-stage product with extended patent protection and the complexity of genetic testing coordination and precision medicine workflows.
Brand ManagerMedical Science Liaison
Worked on ROZLYTREK at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.